Browsing by Subject "Anti-Inflammatory Agents"
Now showing items 1-7 of 7
-
A genetically engineered thermally responsive sustained release curcumin depot to treat neuroinflammation.
(J Control Release, 2013-10-10)Radiculopathy, a painful neuroinflammation that can accompany intervertebral disc herniation, is associated with locally increased levels of the pro-inflammatory cytokine tumor necrosis factor alpha (TNFα). Systemic ... -
Anti-inflammatory effects of progesterone in lipopolysaccharide-stimulated BV-2 microglia.
(PLoS One, 2014)Female sex is associated with improved outcome in experimental brain injury models, such as traumatic brain injury, ischemic stroke, and intracerebral hemorrhage. This implies female gonadal steroids may be neuroprotective. ... -
Changes in serum and synovial fluid biomarkers after acute injury (NCT00332254).
(Arthritis Res Ther, 2010)INTRODUCTION: Acute trauma involving the anterior cruciate ligament is believed to be a major risk factor for the development of post-traumatic osteoarthritis 10 to 20 years post-injury. In this study, to better understand ... -
Characterization of porous, dexamethasone-releasing polyurethane coatings for glucose sensors.
(Acta Biomaterialia, 2014-11)Commercially available implantable needle-type glucose sensors for diabetes management are robust analytically but can be unreliable clinically primarily due to tissue-sensor interactions. Here, we present the physical, ... -
Colchicine effectiveness in symptom and inflammation modification in knee osteoarthritis (COLKOA): study protocol for a randomized controlled trial.
(Trials, 2015-04-30)BACKGROUND: Despite the high prevalence and global impact of knee osteoarthritis (KOA), current treatments are palliative. No disease modifying anti-osteoarthritic drug (DMOAD) has been approved. We recently demonstrated ... -
Emerging treatment options to improve cardiovascular outcomes in patients with acute coronary syndrome: focus on losmapimod.
(Drug Des Devel Ther, 2015)Each year, despite optimal use of recommended acute and secondary prevention therapies, 4%-5% of patients with acute coronary syndrome (ACS) experience relapse of ACS or other cardiovascular events including stroke, heart ... -
Human endotoxin administration as an experimental model in drug development.
(Clin Pharmacol Ther, 2014-10)Linking human physiology to inflammatory mechanisms discovered in vitro or in animal models is essential to determine their importance. Innate immunity underlies many of these inflammatory responses in health and disease. ...
